1. Home
  2. NIE vs DNTH Comparison

NIE vs DNTH Comparison

Compare NIE & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NIE
  • DNTH
  • Stock Information
  • Founded
  • NIE 2007
  • DNTH 2015
  • Country
  • NIE United States
  • DNTH United States
  • Employees
  • NIE N/A
  • DNTH N/A
  • Industry
  • NIE Investment Managers
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • NIE Finance
  • DNTH Health Care
  • Exchange
  • NIE Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • NIE 697.4M
  • DNTH 565.7M
  • IPO Year
  • NIE N/A
  • DNTH N/A
  • Fundamental
  • Price
  • NIE $20.81
  • DNTH $19.50
  • Analyst Decision
  • NIE
  • DNTH Strong Buy
  • Analyst Count
  • NIE 0
  • DNTH 8
  • Target Price
  • NIE N/A
  • DNTH $54.33
  • AVG Volume (30 Days)
  • NIE 70.5K
  • DNTH 418.5K
  • Earning Date
  • NIE 01-01-0001
  • DNTH 05-08-2025
  • Dividend Yield
  • NIE 9.04%
  • DNTH N/A
  • EPS Growth
  • NIE N/A
  • DNTH N/A
  • EPS
  • NIE N/A
  • DNTH N/A
  • Revenue
  • NIE N/A
  • DNTH $6,235,000.00
  • Revenue This Year
  • NIE N/A
  • DNTH N/A
  • Revenue Next Year
  • NIE N/A
  • DNTH N/A
  • P/E Ratio
  • NIE N/A
  • DNTH N/A
  • Revenue Growth
  • NIE N/A
  • DNTH 120.63
  • 52 Week Low
  • NIE $18.61
  • DNTH $13.37
  • 52 Week High
  • NIE $22.47
  • DNTH $32.27
  • Technical
  • Relative Strength Index (RSI)
  • NIE 41.73
  • DNTH 53.31
  • Support Level
  • NIE $20.56
  • DNTH $18.37
  • Resistance Level
  • NIE $21.39
  • DNTH $19.76
  • Average True Range (ATR)
  • NIE 0.79
  • DNTH 1.93
  • MACD
  • NIE 0.05
  • DNTH 0.45
  • Stochastic Oscillator
  • NIE 59.89
  • DNTH 95.93

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: